Drug Database
MO

mometasone furoate (Monovo / H527722 / Mundoson)

✓ Approved

Almirall, S.A · NR3C1 · Small Molecule

What is mometasone furoate?

mometasone furoate is a small molecule developed by Almirall, S.A. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesMonovo, H527722, Mundoson
CompanyAlmirall, S.A
Drug ClassSmall Molecule
Molecular TargetNR3C1, NR3C2
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Almirall, S.A

Mechanism of Action

Molecular Targets

mometasone furoate acts on 2 molecular targets:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
NR3C2nuclear receptor subfamily 3 group C member 2 (NR3C2VIT, MR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

mometasone furoate is developed for 3 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersDermatitis allergic✓ Approved
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

Related Research Articles

PubMedJAMA network open2026-11-10

Inhaled Corticosteroids and Sickle Cell Disease Severity in Adults Without Asthma: A Randomized Clinical Trial.

Curtis Susanna A SA, McCuskee Sarah S, Cohen Robyn T RT, Liu Angela A et al.

People living with sickle cell disease (SCD) who have episodic cough and wheeze (ECW) without a diagnosis of asthma have high rates of pain episodes and acute chest syndrome. A previous trial, in which patients with SCD and ECW without asthma received 15 weeks of inhaled mometasone or placebo, showed that inhaled mometasone improved daily pain and reduced soluble vascular cell adhesion molecule 1 (VCAM-1), a marker of disease severity in SCD. To examine the biologic effects and safety of long-term daily inhaled mometasone in patients without asthma but with SCD and ECW. This placebo-controlled randomized clinical trial recruited patients with SCD from December 2018 to May 2022. Participants were randomly assigned to receive either inhaled mometasone or placebo for 48 weeks. Data analyses followed the modified intention-to-treat principle and were performed between July and November 2023. The inhaled mometasone group received 220 μg of inhaled mometasone furoate dry powder once daily. The placebo group received a matching placebo inhaler. The primary outcome was percentage change in soluble VCAM-1 levels from baseline to end of study. Secondary outcomes included laboratory results, functional outcomes, patient-reported outcomes, and health care utilization. Of the 77 patients who received the intervention and were included in the analysis, 40 were assigned to inhaled mometasone (mean [SD] age, 36.0 [11.6] years; 26 females [65%]) and 37 were assigned to placebo (mean [SD] age, 31.5 [8.6] years; 19 males [51%]). Compared with the placebo group, the inhaled mometasone group increased their soluble VCAM-1 levels by 42% (95% CI, -11% to 96%; P = .02). Point estimates for clinical outcomes favored the placebo group, although the findings were not statistically significant. In this trial of adults with SCD and ECW, extended courses of inhaled mometasone were associated with worsened markers of disease severity. Inhaled mometasone should not be used long-term in patients with SCD and ECW without a definitive diagnosis of asthma. ClinicalTrials.gov Identifier: NCT03758950.

PMID 43007675
Read full article →
PubMedClinical and translational allergy2026-11-08

Onset of Action of Azelastine 0.15% Versus Olopatadine/Mometasone for Allergen-Induced Rhinitis: An EEU Crossover Study.

Bousquet Jean J, Klimek Ludger L, Kuhl Hans-Christian HC, Nguyen Duc Tung DT et al.

The aim of this study was to compare the onset of action (primary), and overall efficacy (secondary) of azelastine nasal spray 0.15% (AZE 0.15%) with mometasone/olopatadine combination therapy (OloMom) in subjects with allergen-induced rhinitis under controlled allergen exposure conditions in an Environmental Exposure Unit (EEU). This was a randomized, double-blind, placebo-controlled, three-period Williams cross-over study. Participants were randomized to receive AZE 0.15%, OloMom, or placebo. Efficacy was assessed during two pollen challenge sections in an EEC, after a single dose and after 3.5 days of treatment. Following a minimum 14-day washout period, subjects received alternate treatment and repeated study procedures until all three interventions were evaluated. The primary endpoint was time to onset of action based on change from baseline in Total Nasal Symptom Score (TNSS). Secondary assessments included total and individual nasal and ocular symptoms and overall efficacy after 3.5 days of treatment. Eighty-four subjects completed the study (mean age 41.5 years; balanced sex distribution), all with confirmed ragweed sensitivity. All treatments reduced TNSS post-dose, with most effective and fastest relief from AZE 0.15%, onset at 15 minutes, sensitivity analyses supported onset at 10 minutes, and greater early nasal, ocular, and total symptom relief compared to OloMom and placebo. AZE 0.15% delivered rapid and clinically significant relief of AR, demonstrating greater early symptoms improvement compared with OloMom. Overall efficacy was comparable between treatments, supporting AZE 0.15% as an effective, steroid-free alternative for rapid symptom control in patients with pollen allergies.

PMID 43000216
Read full article →
PubMedRSC medicinal chemistry2026-11-04

C11-conjugated soft glucocorticoid antibody-drug conjugates for precision immunomodulation.

Yaseen Aiman A AA, Cohen Daniel J DJ, Zhang Anqi A, Tumey L Nathan LN

Glucocorticoids (GCs) are highly effective therapies for inflammatory diseases, but their clinical use is severely limited by systemic toxicities. To address this liability, we developed a modular antibody-drug conjugate (ADC) platform for targeted delivery of GC to immune cells, thereby minimizing systemic exposure to free GC. The platform integrates three key design features: (i) fluticasone furoate (FF), a potent metabolically soft glucocorticoid; (ii) a legumain-cleavable AsnAsnGlyPro self-immolative linker for lysosome-selective payload release; and (iii) C11 hydroxyl conjugation to enhance resistance to serum esterase-mediated hydrolysis. ADCs targeting TNFα, CD38, and CD11a exhibited nanomolar potency in glucocorticoid-responsive reporter assays and excellent serum stability enabled by the C11 conjugation. Across all three targets, the ADCs displayed nanomolar potency in glucocorticoid-responsive reporter assays, achieving over 50-fold selectivity over non-targeting isotype controls. Functional assays in primary bone marrow-derived macrophages (BMDMs) and THP-1 cells confirmed potent inhibition of NF-κB signaling and pro-inflammatory cytokine secretion (IL-6, IL-8). Extensive stability assays in human and mouse serum revealed that the C11-conjugated constructs are highly resistant to premature cleavage. These findings establish a robust, highly stable soft glucocorticoid ADC platform for targeted immunosuppression with the potential to improve the safety and efficacy of glucocorticoid therapy for inflammatory diseases.

PMID 42979242
Read full article →
PubMedJournal of clinical medicine2026-10-27

Real-World Effects of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Chinese Patients with Asthma.

Li Anqi A, Pan Zhouxian Z, Liu Juan J, Li Lun L et al.

Background/Objectives: Asthma is a heterogeneous chronic inflammatory airway disease. In China, achieving rapid asthma control remains a major challenge, and a substantial proportion of patients remain inadequately controlled despite regular use of standard inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) therapy. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) has demonstrated clinical efficacy in trials, but its real-world effectiveness and safety in China remain insufficiently characterized. This study evaluated FF/UMEC/VI (100/62.5/25 μg) in Chinese patients with uncontrolled asthma. Methods: This retrospective study included patients with asthma treated with FF/UMEC/VI at the Department of Allergy, Peking Union Medical College Hospital, between July 2021 and March 2024. The cohort included patients with no prior inhaled medication, irregular prior inhaled therapy, or regular prior inhaled therapy with inadequate control, reflecting a real-world spectrum of patients requiring treatment intensification. Assessments were performed at baseline and 1, 3, and 6 months after treatment initiation. The primary endpoint was the change in forced expiratory volume in 1 s (FEV1) at 1 month. Secondary outcomes included changes in FEV1, percent predicted FEV1, and FEV1/forced vital capacity (FEV1/FVC), and safety. Results: Thirty patients were analyzed. FEV1 increased significantly at 1 month and remained above baseline at 3 and 6 months. Percent predicted FEV1 and FEV1/FVC also improved significantly at all follow-up visits. Maintenance therapy was reduced in 53.3% of patients. No serious adverse events occurred; reported events were mainly local throat discomfort and increased sputum production. Conclusions: In real-world practice, FF/UMEC/VI was associated with improved lung function measures in Chinese patients, including previously untreated, irregularly treated, and regularly treated but uncontrolled patients, with an acceptable safety profile. Larger prospective studies are warranted to confirm its long-term effectiveness and identify appropriate patient populations in China.

PMID 42941503
Read full article →
PubMedAdvances in respiratory medicine2026-10-26

Deciphering the Benefits and Risks of Single-Inhaler Triple Therapy in COPD.

Kopitovic Ivan I, Dimic-Janjic Sanja S, Stjepanovic Mihailo M, Hromis Sanja S et al.

Single-inhaler triple therapy (SITT) combines an inhaled corticosteroid (ICS; for example, fluticasone furoate, budesonide, or beclometasone dipropionate), a long-acting β2-agonist (LABA; for example, vilanterol or formoterol fumarate), and a long-acting muscarinic antagonist (LAMA; for example, umeclidinium or glycopyrronium bromide) in one device. Triple pharmacological therapy reduces exacerbations in selected patients with chronic obstructive pulmonary disease (COPD), but its effects on mortality and cardiovascular outcomes remain uncertain. This structured narrative review summarizes randomized trials, observational comparative-effectiveness studies, target trial emulations, systematic reviews, and health technology assessments published between 2015 and 2026. We grouped the evidence by comparator: LABA/LAMA, ICS/LABA, multiple-inhaler triple therapy (MITT), and ICS continuation versus withdrawal, because each comparison addresses a different clinical question. Pivotal trials and evidence syntheses consistently showed fewer moderate-to-severe exacerbations with triple therapy, with reported rate ratios of approximately 0.69-0.93. Mortality signals from IMPACT and ETHOS are clinically important, but previous ICS use and ICS withdrawal among participants assigned to ICS-free comparators make these findings difficult to interpret. Observational cardiovascular findings are also uncertain because residual confounding, treatment selection, exposure misclassification, outcome misclassification, and differences in baseline disease severity limit causal interpretation. Compared with MITT, the main advantages of SITT are simpler treatment and possible improvements in adherence and persistence, not greater pharmacological potency. Treatment decisions should consider exacerbation history, repeated blood eosinophil counts, pneumonia risk, cardiovascular disease, previous ICS exposure and response, inhaler technique, device suitability, and patient preference. Trials in patients with documented absence of previous ICS use and well-designed target trial emulations are needed to determine whether the observed mortality and cardiovascular associations are causal.

PMID 42930048
Read full article →
PubMedChemSusChem2026-10-20

Valorization of Pentose-Derived Furoates Into 2,5-Furandicarboxylic Acid via Friedel-Crafts Acylation and Amoco Oxidation.

Thiyagarajan Shanmugam S, Angelici Carlo C, van Es Daan S DS, Gruter Gert-Jan M GM

5-Hydroxymethylfurfural (5-HMF), derived from edible C6 sugars, is widely recognized as a key intermediate in established synthetic routes toward 2,5-furandicarboxylic acid (2,5-FDCA), a promising biobased platform chemical. However, reliance on food-based feedstocks presents sustainability and ethical concerns. In this context, nondigestible C5 sugars such as xylose and arabinose-abundant in lignocellulosic agricultural residues-offer an attractive alternative that avoids competition with food resources. Herein, we present a two-step synthetic strategy for the synthesis of 2,5-FDCA starting from 2-furoic acid, a readily accessible derivative of C5 sugars. The first step involves a Friedel-Crafts acylation of methyl 2-furoate using acetic anhydride under acid catalysis, yielding methyl 5-acetyl-2-furoate (1) as the intermediate. Catalyst screening revealed that ZnCl2 achieves complete selectivity toward the desired intermediate at 36% substrate conversion, whereas methanesulfonic acid (MSA) provides higher conversion (59%) with 80% selectivity to (1). In the second step, oxidation of the intermediate under industrially relevant Amoco conditions, employing Co/Mn/Br-based catalytic systems, yields 2,5-FDCA (2) and its monomethyl ester (2a) with combined yields exceeding 95%. Systematic variation of catalyst composition highlights the critical role of the Co/Mn/Br synergy in achieving high oxidation efficiency. This work represents a promising proof-of-concept route that demonstrates accessibility of 2,5-FDCA from pentose-derived intermediates, contributing to enhancing the development of renewable alternatives to petroleum-derived monomers.

PMID 42899486
Read full article →

+2144 more articles available with a free account

Sign up free to view all articles →

Ask about mometasone furoate